228 related articles for article (PubMed ID: 26637742)
1. Surveying the landscape of MDS/MPN research: overlap among the overlap syndromes?
Padron E
Hematology Am Soc Hematol Educ Program; 2015; 2015():349-54. PubMed ID: 26637742
[TBL] [Abstract][Full Text] [Related]
2. Making sense of the myelodysplastic/myeloproliferative neoplasms overlap syndromes.
Tiu RV; Sekeres MA
Curr Opin Hematol; 2014 Mar; 21(2):131-40. PubMed ID: 24378705
[TBL] [Abstract][Full Text] [Related]
3. Traipsing Through Muddy Waters: A Critical Review of the Myelodysplastic Syndrome/Myeloproliferative Neoplasm (MDS/MPN) Overlap Syndromes.
Kuykendall AT; Tokumori FC; Komrokji RS
Hematol Oncol Clin North Am; 2021 Apr; 35(2):337-352. PubMed ID: 33641873
[TBL] [Abstract][Full Text] [Related]
4. Treatment of MDS/MPN and the MDS/MPN IWG International Trial: ABNL MARRO.
Kuykendall AT; Padron E
Curr Hematol Malig Rep; 2019 Dec; 14(6):543-549. PubMed ID: 31776774
[TBL] [Abstract][Full Text] [Related]
5. Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
Patnaik MM; Lasho TL
Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):450-459. PubMed ID: 33275756
[TBL] [Abstract][Full Text] [Related]
6. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations.
Meggendorfer M; Bacher U; Alpermann T; Haferlach C; Kern W; Gambacorti-Passerini C; Haferlach T; Schnittger S
Leukemia; 2013 Sep; 27(9):1852-60. PubMed ID: 23628959
[TBL] [Abstract][Full Text] [Related]
7. Myeloproliferative neoplasms (BCR-ABL1 negative) and myelodysplastic/myeloproliferative neoplasms: current diagnostic principles and upcoming updates.
Geyer JT; Orazi A
Int J Lab Hematol; 2016 May; 38 Suppl 1():12-9. PubMed ID: 27161873
[TBL] [Abstract][Full Text] [Related]
8. MDS overlap disorders and diagnostic boundaries.
Tanaka TN; Bejar R
Blood; 2019 Mar; 133(10):1086-1095. PubMed ID: 30670443
[TBL] [Abstract][Full Text] [Related]
9. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.
Wang SA; Hasserjian RP; Fox PS; Rogers HJ; Geyer JT; Chabot-Richards D; Weinzierl E; Hatem J; Jaso J; Kanagal-Shamanna R; Stingo FC; Patel KP; Mehrotra M; Bueso-Ramos C; Young KH; Dinardo CD; Verstovsek S; Tiu RV; Bagg A; Hsi ED; Arber DA; Foucar K; Luthra R; Orazi A
Blood; 2014 Apr; 123(17):2645-51. PubMed ID: 24627528
[TBL] [Abstract][Full Text] [Related]
10. Myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): More than just a "catch-all" term?
Shallis RM; Zeidan AM
Best Pract Res Clin Haematol; 2020 Jun; 33(2):101132. PubMed ID: 32460977
[TBL] [Abstract][Full Text] [Related]
11. Navigating Myelodysplastic and Myelodysplastic/Myeloproliferative Overlap Syndromes.
Hasserjian RP; Buckstein R; Patnaik MM
Am Soc Clin Oncol Educ Book; 2021 Mar; 41():328-350. PubMed ID: 34010050
[TBL] [Abstract][Full Text] [Related]
12. The utility of a myeloid mutation panel for the diagnosis of myelodysplastic syndrome and myelodysplastic/myeloproliferative neoplasm.
Ibrar W; Zhang W; Cox JL; Cushman-Vokoun A; Fu K; Greiner TC; Yuan J
Int J Lab Hematol; 2021 Dec; 43(6):1501-1509. PubMed ID: 34270867
[TBL] [Abstract][Full Text] [Related]
13. Validation of Molecular International Prognostic Scoring System (IPSS-M) in myelodysplastic/myeloproliferative neoplasms, not otherwise specified (MDS/MPN-NOS).
Mangaonkar AA; Swoboda DM; Lasho TL; Finke C; Ketterling RP; Reichard KK; Komrokji R; Padron E; Patnaik MM
Leuk Res; 2023 Aug; 131():107340. PubMed ID: 37356165
[No Abstract] [Full Text] [Related]
14. Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management".
Patnaik MM; Tefferi A
Am J Hematol; 2021 Mar; 96(3):379-394. PubMed ID: 33428785
[TBL] [Abstract][Full Text] [Related]
15. An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults.
Savona MR; Malcovati L; Komrokji R; Tiu RV; Mughal TI; Orazi A; Kiladjian JJ; Padron E; Solary E; Tibes R; Itzykson R; Cazzola M; Mesa R; Maciejewski J; Fenaux P; Garcia-Manero G; Gerds A; Sanz G; Niemeyer CM; Cervantes F; Germing U; Cross NC; List AF;
Blood; 2015 Mar; 125(12):1857-65. PubMed ID: 25624319
[TBL] [Abstract][Full Text] [Related]
16. Gastrointestinal Behcet's-like disease with myelodysplastic neoplasms with trisomy 8: a French case series and literature review.
Wesner N; Drevon L; Guedon A; Fraison JB; Terrier B; Trad S; Kahn JE; Aouba A; Gillard J; Ponsoye M; Hanslik T; Gourguechon C; Liozon E; Laribi K; Rossignol J; Hermine O; Seksik P; Adès L; Carrat F; Fenaux P; Mekinian A; Fain O;
Leuk Lymphoma; 2019 Jul; 60(7):1782-1788. PubMed ID: 30457024
[TBL] [Abstract][Full Text] [Related]
17. An Exercise in Extrapolation: Clinical Management of Atypical CML, MDS/MPN-Unclassifiable, and MDS/MPN-RS-T.
Talati C; Padron E
Curr Hematol Malig Rep; 2016 Dec; 11(6):425-433. PubMed ID: 27664113
[TBL] [Abstract][Full Text] [Related]
18. Exploring blast composition in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms: CD45RA and CD371 improve diagnostic value of flow cytometry through assessment of myeloblast heterogeneity and stem cell aberrancy.
Shameli A; Dharmani-Khan P; Luider J; Auer I; Shabani-Rad MT
Cytometry B Clin Cytom; 2021 Sep; 100(5):574-589. PubMed ID: 33369070
[TBL] [Abstract][Full Text] [Related]
19. The Challenge of Treating Myelodysplastic Syndromes/Myeloproliferative Neoplasms.
Ragon BK; Savona MR
Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S37-S42. PubMed ID: 28760301
[TBL] [Abstract][Full Text] [Related]
20. Myelodysplastic/myeloproliferative neoplasms.
Foucar K
Am J Clin Pathol; 2009 Aug; 132(2):281-9. PubMed ID: 19605822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
